Dupont Capital Management Corp lowered its position in United Therapeutics Corporation (NASDAQ:UTHR) by 35.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 8,300 shares of the biotechnology company’s stock after selling 4,527 shares during the period. Dupont Capital Management Corp’s holdings in United Therapeutics Corporation were worth $973,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of UTHR. Eagle Global Advisors LLC bought a new position in United Therapeutics Corporation in the 2nd quarter worth $206,000. TLP Group LLC bought a new position in United Therapeutics Corporation in the 2nd quarter worth $246,000. HPM Partners LLC boosted its holdings in United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after buying an additional 15 shares during the period. Fort L.P. boosted its holdings in United Therapeutics Corporation by 5.2% in the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock worth $261,000 after buying an additional 99 shares during the period. Finally, Prospera Financial Services Inc bought a new position in United Therapeutics Corporation in the 2nd quarter worth $277,000.

In other news, CEO Martine A. Rothblatt sold 1,235 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $131.95, for a total transaction of $162,958.25. Following the sale, the chief executive officer now directly owns 2,304 shares in the company, valued at approximately $304,012.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher Causey sold 580 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $134.48, for a total transaction of $77,998.40. Following the sale, the director now owns 3,295 shares in the company, valued at $443,111.60. The disclosure for this sale can be found here. Insiders have sold a total of 16,793 shares of company stock worth $2,081,621 over the last 90 days. Corporate insiders own 7.80% of the company’s stock.

Several research analysts recently weighed in on UTHR shares. Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a report on Friday, July 14th. BidaskClub downgraded shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. ValuEngine downgraded shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. Finally, Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 3rd. Five research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $132.82.

TRADEMARK VIOLATION WARNING: “United Therapeutics Corporation (UTHR) Position Trimmed by Dupont Capital Management Corp” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-position-trimmed-by-dupont-capital-management-corp/1695449.html.

United Therapeutics Corporation (UTHR) opened at $121.00 on Friday. The company has a market cap of $5,238.48, a PE ratio of 10.69 and a beta of 1.38. United Therapeutics Corporation has a 1-year low of $112.01 and a 1-year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million for the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The business’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company earned $4.23 EPS. equities analysts anticipate that United Therapeutics Corporation will post 11.92 earnings per share for the current year.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.